Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GlaxoSmithKline Licenses Vectura’s Dry Powder Drug Formulation Patents

By Pharmaceutical Processing | August 6, 2010

Vectura Group plc announced that Glaxo Group Limited and GlaxoSmithKline Research & Development Limited have signed a worldwide non-exclusive agreement to license some of Vectura’s dry powder drug formulation patents in relation to two late stage development compounds in GSK’s respiratory product pipeline.

Under the terms of the agreement, Vectura will receive up to £20 million in up-front and milestone payments. An initial up-front payment of £10 million will be received in September 2010 with the remaining £10 million expected to be received by the time both compounds are launched. In addition, Vectura will earn royalties capped at certain levels of sales of these products. The maximum annual royalties payable to Vectura under this license agreement will be £13 million.

The majority of treatments for asthma and COPD are delivered by inhalation. Global markets for these treatments are valued in excess of $25 billion today and are expected to grow by 30% over the next 10 years. Vectura remains focused on the respiratory market. With the benefit of Vectura’s range of enabling technologies, including both inhalation devices and formulation technologies, the Company is well placed to capture value from this large market in a number of ways. Today’s deal with GSK, one of the world’s leading companies developing therapies for the treatment of asthma and COPD, is one such example.

Dr Chris Blackwell, Chief Executive of Vectura, commented: “GSK is one of the world’s leading developers of innovative respiratory medicines and I believe this deal reflects the importance of Vectura’s respiratory technology IP. The non-exclusive nature of this agreement also allows us to continue our efforts to deliver further value for shareholders from our inhaled therapy technologies in the future”

 

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE